From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function

David Medina-Julio; Mariana M. Ramírez-Mejía; Jacqueline Cordova-Gallardo; Emilio Peniche-Luna; Carlos Cantú-Brito; Nahum Méndez-Sánchez

doi:10.12659/MSM.943417

29 January 2024: Review Articles

From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function

David Medina-Julio ^12AEF , Mariana M. Ramírez-Mejía ^34EF , Jacqueline Cordova-Gallardo ^25AEF , Emilio Peniche-Luna ^6EF , Carlos Cantú-Brito ^27AF , Nahum Mendez-Sanchez ^23AEF*

DOI: 10.12659/MSM.943417

Med Sci Monit 2024; 30:e943417

Authors information Article notes Copyright and License information

Background Epidemiology Risk Factors: The Interplay of MetS, MAFLD/MASLD, and Cognitive Function Mechanisms Underlying Cognitive Impairment in MAFLD/MASLD The Brain–Gut–Liver Axis Neurological Manifestations Challenges and Treatment Future Directions Conclusions References

View HTML version

Figure 2 Exploring the link between MAFLD/MASLD, insulin resistance, and cognitive impairmentInsulin resistance serves as a central node linking MAFLD/MASLD to systemic effects, influencing both metabolic and cognitive health. The figure shows potential pathways and shared risk factors. Understanding these intricate relationships is vital for advancing holistic approaches to health and potential interventions. BBB – blood–brain barrier. Created using Biorender.

Back to the Article

From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function

Your Privacy